Evidence map›Paper›PMID 41791388›Full record

ArticleStem cell reports2026

Genome-edited safe and immune-evasive human pluripotent cells: Potential solution for allogeneic therapies.

Vivian Tam, Nicole Ching Man Wong, Andrew Chung Hin Poon, Mengxia Zhu, Ting Mei, Janette Kwok, Patrick Chu, Eric D Jong, Jean Kit Tang, Andras Nagy and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vivian TamSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Nicole Ching Man WongSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Andrew Chung Hin PoonSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Mengxia ZhuSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Ting MeiSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Janette KwokDivision of Transplantation & Immunogenetics, Department of Pathology, Queen Mary Hospital, Hong Kong SAR, China.
Patrick ChuDivision of Transplantation & Immunogenetics, Department of Pathology, Queen Mary Hospital, Hong Kong SAR, China.
Eric D JongLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
Jean Kit TangLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada; Department of Physiology, University of Toronto, Toronto, ON, Canada.
Andras NagyLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada; Department of Obstetrics & Gynaecology and Institute of Medical Science, University of Toronto, Toronto, ON, Canada. Electronic address: nagy@lunenfeld.ca.
Danny ChanSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Electronic address: chand@hku.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We used an embryonic stem cell line (H1) engineered for immune-evading properties to avoid rejection ("AlloAccept") and equipped with a "SafeCell" (SC) kill-switch to eliminate aberrantly proliferating cells. Utilizing a humanized immune system mouse model, we demonstrated the successful generation of allogeneic tissues from SafeCell-AlloAccept (SC-AlloAccept) cells in immunocompetent humanized mice in the immune-active subcutaneous region. These cells formed various tissue types, and their growth can be controlled with pro-drug ganciclovir to activate the kill switch, which eliminated proliferating cells and rendered the remaining tissue dormant. Strikingly, SC-AlloAccept-derived grafts survived for 5 months, underscoring their potential for long-term engraftment. Importantly, neither prior rejection of immunogenic parental H1 cells (sensitization) nor the presence of immune-evasive H1-derived tissue (potential immunocompromising) affected the immune response to a subsequent second transplant. This study validated the utility of SC-AlloAccept human cells in transplantation and enhanced the safety and efficacy of stem cell-based regenerative therapies.

Indexed as

Pluripotent Stem CellsAnimalsCell LineHumansMiceTransplantation, HomologousAlloAcceptallogeneic transplantationcell therapyhumanized immune systemhuman pluripotent stem cellimmune evasionkill switchlong-term engraftmentregenerative medicineuniversal cell source

Identifiers

PMID41791388
PMCPMC13083796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.